Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000498824 | SCV000589511 | pathogenic | not provided | 2023-03-31 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Reported as a de novo variant in a patient with a developmental disorder who also harbored a de novo variant in the PCDHGA10 gene (Turner et al., 2019); Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 30440138, 20513142, 31785789) |
Labcorp Genetics |
RCV001071342 | SCV001236639 | pathogenic | Intellectual disability, autosomal dominant 20 | 2019-12-04 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Loss-of-function variants in MEF2C are known to be pathogenic (PMID: 20513142). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. This variant has been observed in individual(s) with clinical features of MEF2C-related conditions (PMID: 30440138). This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Gln18*) in the MEF2C gene. It is expected to result in an absent or disrupted protein product. |
Genetic Services Laboratory, |
RCV000498824 | SCV002069099 | pathogenic | not provided | 2018-02-22 | criteria provided, single submitter | clinical testing | |
Genome |
RCV000509200 | SCV000606922 | not provided | MEF2C-related disorder | no assertion provided | phenotyping only | GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. |